Dr. Eric J. Miller, MD
Medical Oncology (Medical Oncology Physician)
At a glance
- Medical school
- University of Arizona College of Medicine (2019)
- Years since graduation
- 7
- In the NPI registry since
- 2019
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2019Medical school: University of Arizona College of Medicine
- 2019Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 316141
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Sinai Hospital New York, NY
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 5 companies reported 8 payments worth $444 in total to this clinician.
| Pfizer Inc. | $196 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $152 |
| Merck Sharp & Dohme LLC | $43.56 |
| Progenics Pharmaceuticals, Inc. | $30.27 |
| Daiichi Sankyo Inc. | $21.67 |
| Food and Beverage | $444 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $228,945 in research payments for these studies, mostly to the institutions running them.
- A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Rena…
Merck Sharp & Dohme LLC - A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC IDeate-Prostate01
Merck Sharp & Dohme LLC - A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT03972657
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.